Real-World Treatment Patterns and Clinical Outcomes Among Patients with Metastatic Adenocarcinoma of the Prostate

Real-World Treatment Patterns and Clinical Outcomes Among Patients with Metastatic Adenocarcinoma of the Prostate.

This is a multicentric, non-interventional, real-world observational study involving the review of pertinent data from medical records.

The study cohort will consist of all patients who meet the eligibility criteria. The date of metastatic prostate cancer diagnosis will define the study index date (T1), which must occur during the case selection window of 01 January 2023 onwards. The selection of these study dates is based on consideration of the anticipated data collection date, the need to document current treatment patterns (from the first-line metastatic setting), and allowance of at least 18-month follow-up opportunity for the assessment of study outcomes, particularly OS.

The time of metastatic prostate cancer diagnosis (T1) will represent the baseline. The baseline characteristics and treatment history prior to T1 will be assessed. The follow-up period will begin on the index date (T1). Patients will be followed until date of death or the date of last recorded medical visit. Patients who died before 18 months of follow-up and patients who have less than 18 months of follow-up as of their last recorded medical visit will be allowed into the study. All patient medical records that occur during follow-up will be reviewed and data on treatment regimens, treatment characteristics, clinical outcomes, and

resource use will be extracted. Consistent with the routine-care of mCSPC and mCRPC patients and differences in healthcare systems across the country (India), the follow-up visits are likely to be different.